Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug

Yoshitsugu Fujioka, Yukiko Metsugi, Ken ichi Ogawara, Kazutaka Higaki, Toshikiro Kimura

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Mean plasma concentration-time profile of griseofulvin, a BCS class II drug, orally administered as powders into rats, was predicted based on GITA model. However, it was very difficult to predict the individual plasma profile because of large inter-individual difference. As the absorption of griseofulvin would be rate-limited by the dissolution process, we tried to analyze the in vivo dissolution kinetics of griseofulvin by focusing on gastric emptying and intestinal transit as physiological factors influencing the in vivo dissolution kinetics. After oral administration of griseofulvin, theophylline and sulfasalazine into rats, gastric emptying and intestinal transit were simultaneously estimated by analyzing the absorption kinetics of theophylline and observing the appearance of sulfapyridine in plasma, respectively. Gastric emptying kinetics was not significantly correlated with absorption or dissolution behavior of griseofulvin. On the other hand, the cecum-arriving time reflecting the intestinal transit was significantly correlated with both AUC and total dissolved amount of griseofulvin. Tmax of griseofulvin also increased with the increase of cecum-arriving time. These results clearly indicate that the longer residence time could lead to the higher dissolution and absorption of griseofulvin and that the variance of intestinal transit could be responsible for the inter-individual difference of the in vivo absorption behavior.

Original languageEnglish
Pages (from-to)36-43
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume352
Issue number1-2
DOIs
Publication statusPublished - Mar 20 2008

Fingerprint

Griseofulvin
Pharmaceutical Preparations
Gastric Emptying
Cecum
Theophylline
Individuality
Sulfapyridine
Sulfasalazine
Powders
Area Under Curve
Oral Administration

Keywords

  • Biopharmaceutics classification system class II
  • Cecum-arriving time
  • Gastric emptying
  • Griseofulvin
  • In vivo dissolution
  • Intestinal transit

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. / Fujioka, Yoshitsugu; Metsugi, Yukiko; Ogawara, Ken ichi; Higaki, Kazutaka; Kimura, Toshikiro.

In: International Journal of Pharmaceutics, Vol. 352, No. 1-2, 20.03.2008, p. 36-43.

Research output: Contribution to journalArticle

Fujioka, Yoshitsugu ; Metsugi, Yukiko ; Ogawara, Ken ichi ; Higaki, Kazutaka ; Kimura, Toshikiro. / Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. In: International Journal of Pharmaceutics. 2008 ; Vol. 352, No. 1-2. pp. 36-43.
@article{b738509e7c6e44d3aba7712c8ad92640,
title = "Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug",
abstract = "Mean plasma concentration-time profile of griseofulvin, a BCS class II drug, orally administered as powders into rats, was predicted based on GITA model. However, it was very difficult to predict the individual plasma profile because of large inter-individual difference. As the absorption of griseofulvin would be rate-limited by the dissolution process, we tried to analyze the in vivo dissolution kinetics of griseofulvin by focusing on gastric emptying and intestinal transit as physiological factors influencing the in vivo dissolution kinetics. After oral administration of griseofulvin, theophylline and sulfasalazine into rats, gastric emptying and intestinal transit were simultaneously estimated by analyzing the absorption kinetics of theophylline and observing the appearance of sulfapyridine in plasma, respectively. Gastric emptying kinetics was not significantly correlated with absorption or dissolution behavior of griseofulvin. On the other hand, the cecum-arriving time reflecting the intestinal transit was significantly correlated with both AUC and total dissolved amount of griseofulvin. Tmax of griseofulvin also increased with the increase of cecum-arriving time. These results clearly indicate that the longer residence time could lead to the higher dissolution and absorption of griseofulvin and that the variance of intestinal transit could be responsible for the inter-individual difference of the in vivo absorption behavior.",
keywords = "Biopharmaceutics classification system class II, Cecum-arriving time, Gastric emptying, Griseofulvin, In vivo dissolution, Intestinal transit",
author = "Yoshitsugu Fujioka and Yukiko Metsugi and Ogawara, {Ken ichi} and Kazutaka Higaki and Toshikiro Kimura",
year = "2008",
month = "3",
day = "20",
doi = "10.1016/j.ijpharm.2007.10.008",
language = "English",
volume = "352",
pages = "36--43",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug

AU - Fujioka, Yoshitsugu

AU - Metsugi, Yukiko

AU - Ogawara, Ken ichi

AU - Higaki, Kazutaka

AU - Kimura, Toshikiro

PY - 2008/3/20

Y1 - 2008/3/20

N2 - Mean plasma concentration-time profile of griseofulvin, a BCS class II drug, orally administered as powders into rats, was predicted based on GITA model. However, it was very difficult to predict the individual plasma profile because of large inter-individual difference. As the absorption of griseofulvin would be rate-limited by the dissolution process, we tried to analyze the in vivo dissolution kinetics of griseofulvin by focusing on gastric emptying and intestinal transit as physiological factors influencing the in vivo dissolution kinetics. After oral administration of griseofulvin, theophylline and sulfasalazine into rats, gastric emptying and intestinal transit were simultaneously estimated by analyzing the absorption kinetics of theophylline and observing the appearance of sulfapyridine in plasma, respectively. Gastric emptying kinetics was not significantly correlated with absorption or dissolution behavior of griseofulvin. On the other hand, the cecum-arriving time reflecting the intestinal transit was significantly correlated with both AUC and total dissolved amount of griseofulvin. Tmax of griseofulvin also increased with the increase of cecum-arriving time. These results clearly indicate that the longer residence time could lead to the higher dissolution and absorption of griseofulvin and that the variance of intestinal transit could be responsible for the inter-individual difference of the in vivo absorption behavior.

AB - Mean plasma concentration-time profile of griseofulvin, a BCS class II drug, orally administered as powders into rats, was predicted based on GITA model. However, it was very difficult to predict the individual plasma profile because of large inter-individual difference. As the absorption of griseofulvin would be rate-limited by the dissolution process, we tried to analyze the in vivo dissolution kinetics of griseofulvin by focusing on gastric emptying and intestinal transit as physiological factors influencing the in vivo dissolution kinetics. After oral administration of griseofulvin, theophylline and sulfasalazine into rats, gastric emptying and intestinal transit were simultaneously estimated by analyzing the absorption kinetics of theophylline and observing the appearance of sulfapyridine in plasma, respectively. Gastric emptying kinetics was not significantly correlated with absorption or dissolution behavior of griseofulvin. On the other hand, the cecum-arriving time reflecting the intestinal transit was significantly correlated with both AUC and total dissolved amount of griseofulvin. Tmax of griseofulvin also increased with the increase of cecum-arriving time. These results clearly indicate that the longer residence time could lead to the higher dissolution and absorption of griseofulvin and that the variance of intestinal transit could be responsible for the inter-individual difference of the in vivo absorption behavior.

KW - Biopharmaceutics classification system class II

KW - Cecum-arriving time

KW - Gastric emptying

KW - Griseofulvin

KW - In vivo dissolution

KW - Intestinal transit

UR - http://www.scopus.com/inward/record.url?scp=39449086202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449086202&partnerID=8YFLogxK

U2 - 10.1016/j.ijpharm.2007.10.008

DO - 10.1016/j.ijpharm.2007.10.008

M3 - Article

VL - 352

SP - 36

EP - 43

JO - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1-2

ER -